Article Text

other Versions

PDF
Sentinel lymph node biopsy for in situ melanoma is unlikely in Australia
  1. Rachael L Morton1,2,
  2. John F Thompson2
  1. 1 NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, Australia
  2. 2 Melanoma Institute Australia, North Sydney, New South Wales, Australia
  1. Correspondence to Associate Professor Rachael L Morton, NHMRC Clinical Trials Centre, Camperdown, NSW 2050, Australia; rachael.morton{at}ctc.usyd.edu.au

Statistics from Altmetric.com

We commend Badgery-Parker and colleagues for their comprehensive review of ‘low-value’ healthcare provided at public hospitals in New South Wales (NSW), Australia and support their initiative to identify low-value care.1 In relation to melanoma in situ, we agree completely with the Evaluating Evidence Enhancing Efficiences (EVOLVE) guidelines2 that there is no evidence that sentinel node (SN) biopsy for this entity is beneficial and also agree that it would constitute low-value care if performed. However, there appears to be a serious methodological flaw in the study by Badgery-Parker et al which may have led to the erroneous claim that SN biopsy for melanoma in situ is being performed in NSW public hospitals and ‘requires action to reverse increasing trends’.

The authors used public hospital admitted-patient data to identify SN biopsy procedures and International Statistical Classification of Diseases and …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles